At present, a pandemic of antibiotic-resistant infectious diseases is an evergrowing threat. The need for new antibiotics and ways to combat antibiotic resistance is glaring. This review will focus on two different privileged scaffolds, the indole and the indoline, as useful nuclei for novel antibacterial compounds. The indole, a moiety found in numerous approved drugs for many disease states, has recently been studied for its usefulness as a scaffold for compounds that have activity against antibiotic-resistant bacteria, especially against methicillin-resistant Staphylococcus aureus (MRSA). The indoline is a scaffold with significantly less historical studies and FDA-approved drugs and it has attracted new interest in drug design and development. In recent years, indoline-containing compounds have been shown to have antibacterial activity as well as activity as a resistance- modifying agent (RMA), which act to improve the effectiveness of current antibiotic therapies that have known resistance.

目前，抗生素耐药性传染病的大流行是一个不断增长的威胁。迫切需要新的抗生素和对抗抗生素耐药性的方法。本综述将重点关注两种不同的特权支架，吲哚和二氢吲哚，它们是新型抗菌化合物的有用细胞核。吲哚是在许多已批准的治疗多种疾病的药物中发现的一种成分，最近研究了它作为化合物支架的有用性，这些化合物具有抗抗生素抗性细菌，尤其是抗甲氧西林金黄色葡萄球菌 (MRSA) 的活性。二氢吲哚是一种历史研究和 FDA 批准药物显着减少的支架，它引起了对药物设计和开发的新兴趣。最近几年，